The long-term outcome of patients with polycystic liver disease treated with lanreotide

What Was Tested

Researchers studied Somatostatin and Lanreotide in this randomized controlled trial publication.

To establish long-term outcome and safety of lanreotide.

Why It Was Studied

Polycystic liver disease (PLD) is a phenotypical expression of autosomal dominant polycystic kidney disease and isolated polycystic liver disease.

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

The length of total treatment was 12 months.

Primary endpoint was relative change in liver volume, as determined by CT-volumetry after 12 months of treatment.

How the Study Was Run

The design is described as randomized, open-label and placebo-controlled.

Because people in this Somatostatin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Being open-label, the Somatostatin study did not mask who received what.

The comparison arm used a placebo, so changes seen with Somatostatin could be set against what happens without it.

The methods mention a period of 12 months.

The researchers offered patients a CT scan 6 months after stopping lanreotide.

What Was Measured

PubMed files the paper under topics including Antineoplastic Agents, Cysts, Liver, Liver Diseases, Liver Function Tests, Peptides, Cyclic and Somatostatin.

What This Means in Plain Language

The paper is a randomized, open-label and placebo-controlled study of Somatostatin and Lanreotide over 12 months.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2012 (Alimentary pharmacology & therapeutics), a journal based in England.

More context: the Somatostatin compound page and the Lanreotide compound page, all human trials.